{
    "clinical_study": {
        "@rank": "85575", 
        "acronym": "SOUTH", 
        "arm_group": {
            "arm_group_label": "anti-tuberculosis drugs", 
            "arm_group_type": "Other", 
            "description": "Rifampicin, Isoniazid, Ethambutol, Pyrazinamide tablets 3 to 5 tablets once daily for 2 months followed by Rifampicin, Isoniazid 3 to 5 tablets once daily for 4 months"
        }, 
        "brief_summary": {
            "textblock": "Tuberculosis (TB) is a leading cause of death in HIV-infected individuals. There are\n      insufficient data correlating concentrations of anti-TB drugs with treatment response. We\n      hypothesize that sub-therapeutic concentrations of anti-TB drugs are associated with\n      inadequate TB treatment response to Mycobacterium tuberculosis."
        }, 
        "brief_title": "Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "AIDS With Tuberculosis", 
        "condition_browse": {
            "mesh_term": "Tuberculosis"
        }, 
        "detailed_description": {
            "textblock": "During the study periodic monitoring will be conducted to ensure that the protocol and Good\n      Clinical Practices (GCPs) are being followed.The monitors may review source documents to\n      confirm that the data recorded on CRFs is accurate. The study site may be subject to review\n      by the Institutional Review Board (IRB) and/or appropriate regulatory authorities.\n\n      A CRF will be completed for each included subject and will be signed by the investigator or\n      by an authorized staff member to attest that the data is true. Any corrections to entries\n      made in the CRFs, source documents must be dated, initialed and explained (if necessary) and\n      should not obscure the original entry. Qualit assurance will as also be performed regularly\n      on the CRFs.\n\n      The primary end point will be analyzed using Time to event (cure, death, relapse\n      etc)analysis and failure rates and hazard ratios will be calculated accordig to categorical\n      drug concentrations with proposed cutt offs.\n\n      Secondary end points will be analysed using time to event for occurence of toxicities which\n      will also be corelated to the drug concentrations."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Evidence of a personally signed and dated informed consent\n\n          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,\n             laboratory tests, and other study procedures.\n\n          -  Age of \u226518 years\n\n          -  First episode of pulmonary TB i.e. proven or highly suspected TB considered for TB\n             treatment qualifying for 6 months anti-Tb drugs regimen\n\n          -  Confirmed HIV-1 infection\n\n        Exclusion Criteria:\n\n          -  Unable to provide informed consent\n\n          -  Documented or highly suspected TB infection of any organs/systems other   than the\n             lung requiring TB treatment longer than 6 months\n\n          -  Previously treated for a mycobacterial infection (TB or atypical mycobacterial\n             infection, active or latent)\n\n          -  Pregnancy or planned pregnancy within the next year\n\n          -  Unwillingness to perform pregnancy test\n\n          -  Decompensated liver disease and/or aminotransferases >5x ULN\n\n          -  GFR < 50 ml/min\n\n          -  Co-morbidities reducing life expectancy to <1 year (e.g. cancer)\n\n          -  Patient wishes to take part in another interventional study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01782950", 
            "org_study_id": "IDI"
        }, 
        "intervention": {
            "arm_group_label": "anti-tuberculosis drugs", 
            "description": "Rifampicin, Isoniazid, Ethambutol, Pyrazinamide: 3, 4 or 5 tablets daily for weight below 55kg, above 55kg or above 70kg respectively for first 2 months followed by Rifampicin, Isoniazid: 3, 4 or 5 tablets daily for patients' weight below 55kg, above 55kg or above 70kg respectively for 4 months", 
            "intervention_name": "Rifampicin, Isoniazid, Ethambutol, Pyrazinamide", 
            "intervention_type": "Drug", 
            "other_name": [
                "Forecox Trac", 
                "and Montozid"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antitubercular Agents", 
                "Ethambutol", 
                "Isoniazid", 
                "Pyrazinamide", 
                "Rifampin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HIV", 
            "Tuberculosis", 
            "Antituberculosis drugs"
        ], 
        "lastchanged_date": "February 1, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kampala", 
                    "country": "Uganda"
                }, 
                "name": "Infectious Diseases Institute"
            }, 
            "investigator": {
                "last_name": "Barbara Castelnuovo, MBChB, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Uganda"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults", 
        "overall_contact": {
            "email": "akambugu@idi.co.ug", 
            "last_name": "Andrew Kambugu, MBChB, PhD", 
            "phone": "+256-414-307291"
        }, 
        "overall_official": {
            "affiliation": "Infectious Diseases Institute", 
            "last_name": "Barbara Castelnuovo, MBChB, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Uganda: National Council for Science and Technology", 
                "Uganda: National Drug Authority", 
                "Uganda: Research Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To investigate the association between serum concentrations of antituberculosis drugs and tuberculosis treatment response in HIV-TB-co-infected individuals.", 
            "measure": "clinical outcome", 
            "safety_issue": "No", 
            "time_frame": "At the end of treatment (6 months after enrolmet)"
        }, 
        "reference": [
            {
                "PMID": "19432554", 
                "citation": "Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, Reingold AL, Kenyon TA, Moeti TL, Tappero JW. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis. 2009 Jun 15;48(12):1685-94. doi: 10.1086/599040."
            }, 
            {
                "PMID": "15844071", 
                "citation": "Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B, Silva-Trigo C, Zhao Z, Hodge T; Tuberculosis Trials Consortium. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis. 2005 May 15;40(10):1481-91. Epub 2005 Apr 14."
            }, 
            {
                "PMID": "15504887", 
                "citation": "Gurumurthy P, Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Padmapriyadarsini C, Swaminathan S, Bhagavathy S, Venkatesan P, Sekar L, Mahilmaran A, Ravichandran N, Paramesh P. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother. 2004 Nov;48(11):4473-5."
            }, 
            {
                "PMID": "11170964", 
                "citation": "Narita M, Hisada M, Thimmappa B, Stambaugh J, Ibrahim E, Hollender E, Ashkin D. Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors. Clin Infect Dis. 2001 Feb 1;32(3):515-7. Epub 2001 Jan 25."
            }, 
            {
                "PMID": "17724157", 
                "citation": "Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother. 2007 Nov;51(11):3781-8. Epub 2007 Aug 27."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01782950"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Makerere University", 
            "investigator_full_name": "Infectious Diseases Institute", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To investigate the steady-state pharmacokinetic parameters of anti-TB drugs at different time-points over the course of TB-treatment", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "At 2 weeks, 8 weeks and 24 weeks after anti-tuberculosis drug initiation"
            }, 
            {
                "description": "To assess the safety and tolerability of anti-TB drugs based on the WHO guidelines", 
                "measure": "Number of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "2 weeks, 8 weeks and 24 weeks after anti-tuberculosis drug initiation"
            }, 
            {
                "description": "To correlate the effect of anti-TB drugs on plasma concentrations of efavirenz or protease inhibitors and vice versa.", 
                "measure": "ART trough levels", 
                "safety_issue": "No", 
                "time_frame": "At 2 weeks, 8 weeks and 24 weeks after anti-tuberculosis drug initiation"
            }, 
            {
                "description": "To evaluate the effect of acetylator geno-and phenotype (NAT-2 gene) on isoniazid plasma concentrations and toxicity", 
                "measure": "Isoniazid Cmax", 
                "safety_issue": "Yes", 
                "time_frame": "At 2 weeks, 8 weeks and 24 weeks"
            }
        ], 
        "source": "Makerere University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Makerere University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}